

Supplementary Table SI. Search strategies for databases

Database	Search strategy	Number of received articles
PubMed	((("Cardiac Myosin Inhibitors"[Title/Abstract] OR "Mavacamten"[Title/Abstract] OR "Aficamten"[Title/Abstract]) AND ("Hypertrophic Cardiomyopathy"[MeSH Terms] OR "HCM"[Title/Abstract] OR "Non-obstructive Hypertrophic Cardiomyopathy"[Title/Abstract] OR "Obstructive Hypertrophic Cardiomyopathy"[Title/Abstract]) AND ("Randomized Controlled Trials as Topic"[MeSH Terms] OR "RCT"[Title/Abstract])) AND ("Randomized Controlled Trials as Topic"[MeSH Terms] OR "RCT"[Title/Abstract]))	232
Cochrane	((("Cardiac Myosin Inhibitors" OR "Mavacamten" OR "Aficamten") AND ("Hypertrophic Cardiomyopathy" OR "Obstructive Hypertrophic Cardiomyopathy" OR "Non-obstructive Hypertrophic Cardiomyopathy") AND ("Left Ventricular Outflow Tract Obstruction" OR "Functional Capacity"))	14
Google Scholar	"Cardiac Myosin Inhibitors" OR "Mavacamten" OR "Aficamten" AND "Hypertrophic Cardiomyopathy" OR "HCM" AND "LVOT Obstruction" OR "Functional Capacity" AND "Randomized Controlled Trials"	136


Supplementary Figure S1. Evaluation of risk of bias in included studies

		Risk of bias domains					
		D1	D2	D3	D4	D5	Overall
Study	SEQUOIA-HCM						
	EXPLORER-HCM						
	REDWOOD-HCM						
	EXPLORER-CN						
	MAVERICK-HCM						
	VALOR-HCM						

Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.


Judgement
 Some concerns
 Low

Supplementary Figure S2. Forest plot showing the mean difference of NT-proBNP in patients with HCM treated with a myosin inhibitor versus placebo




Forest plot showing the mean difference of NT-proBNP in patients with HCM from baseline

Supplementary Figure S3. Forest plot showing the mean difference of NT-proBNP in patients with HCM treated with a myosin inhibitor versus placebo




Forest plot showing the mean difference of cTnI in patients with HCM from baseline

Supplementary Figure S4. Forest plot showing the mean difference of LVEF in patients with HCM treated with a myosin inhibitor versus placebo




Forest plot showing the mean difference of LVEF in patients with HCM from baseline

Supplementary Figure S5. Forest plot showing the risk of TEAs in patients with HCM treated with a myosin inhibitor versus placebo



Patients with any Treatment emergent adverse events (TEAs)

Supplementary Figure S6. Forest plot showing the risk of SAEs in patients with HCM treated with a myosin inhibitor versus placebo



Patients with any Serious adverse events (SAEs)